Top Conversations from 2023 Tandem Meetings
Catch up with some of CGTLive’s top conversations from the annual ASTCT and CIBMTR meeting.
The 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19, 2023, showcased new data in both solid and liquid tumors, rare diseases, and hematologic disorders. The meeting brought together clinicians to discuss and share ideas, and CGTLive was onsite to interview them and provide live coverage of the meeting. Catch up on some of our top conversations from the meeting below.
Nirav Shah, MD, on New Data on Zamto-cel in DLBCL, Mantle Cell Lymphoma
The associate professor of medicine at Medical College of Wisconsin discussed trials assessing the dual, CD19/CD20-targeting CAR T therapy, zamto-cel and the advantages and research being conducted with dual-targeting CAR T therapies. He outlined the data presented and highlighted the favorable safety profile of the therapy.
Madeleine Powys, MBBS, on Delivering Libmeldy to Children With Metachromatic Leukodystrophy
The locum consultant of pediatric BMT and leukemia at Royal Manchester Children’s Hospital discussed the limited distribution model of arsa-cel in Europe. She shared her experience delivering arsa-cel to children and challenges that remain. She also stressed the importance of increasing awareness of later-onset forms of MLD to enable treatment in these populations.
Christa Krupski, DO, MPH, on Reinfusion of Tisagenlecleucel in B-ALL
The hematologist/oncologist at Cincinnati Children’s discussed unfavorable outcomes with tisa-cel reinfusion in patients with B-cell acute lymphocytic leukemia. She discussed the rationale for the study and the questions that remain to be investigated with reinfusion of a chimeric antigen receptor (CAR) T-cell receptor therapy. She overviewed the study conducted and the findings presented at the meeting, which included only short responses, if any, in the study participants.
Surbhi Sidana, MD, on Assessing Ide-cel in Patients With R/R Multiple Myeloma and Renal Impairment
The assistant professor of medicine, bone marrow transplantation and cellular therapy, Stanford, discussed favorable data from a real-world experience study and why it is important to assess ide-cel and other CAR T-cell therapies in populations not evaluated in clinical trials. She stressed the study’s conclusions that patients with RRMM and renal impairment should not be excluded from ide-cel treatment.
Bhagirathbhai Dholaria, MBBS, on Administering Axi-Cel in the Outpatient Setting for LBCL
The assistant professor of medicine at Vanderbilt University Medical Center discussed results from a retrospective analysis presented at the 2023 Tandem Meetings and the favorable outcomes observed in patients treated in the outpatient setting. He discussed the advantages for both patients and hospitals with outpatient chimeric antigen receptor (CAR) T-cell therapy treatments.
Brian Van Tine, MD, PhD, on Bringing Cell Therapy Into Synovial Sarcoma Treatment
The professor medicine and pediatrics at Washington University in St. Louis overviewed data from the SPEARHEAD-1 trial of afami-cel and how the therapy could potentially improve outcomes for patients with synovial sarcoma, a disease area that has previously not seen many novel therapies. He overviewed the data generated and how it has favorably matured.
Everett Meyer, MD, PhD, on Reducing GvHD in Leukemia Treatment
The assistant professor of medicine and pediatrics at Stanford University discussed updated data from 2 studies of Orca-T cell therapy and Orca-T's demonstrated benefit in treating leukemias while maintaining a lower incidence of GvHD compared to historical data with allogeneic stem cell transplant (ASCT). He also discussed the first ever National GvHD Awareness Day.
Matthew Frank, MD, PhD, on Investigation CD22 CAR for LBCL After CD19 Relapse
The assistant professor of BMT and cellular therapy discussed updated safety and efficacy data on CD22 CAR T-cell therapy and how it could help address the unmet need in patients with LBCL that relapse after CAR T-cell therapy. He overviewed the manageable safety profile and promising efficacy signals seen with CD22 CAR.
